抗パーキンソン病薬の世界市場：～2030年

世界の抗パーキンソン病薬の市場規模は、2025年の61億米ドルから、2025年から2030年にかけてはCAGR 8.6%で推移し、2030年末には92億米ドルに達すると予測されています。

北米市場は、2025年の35億米ドルから、予測期間中は9.5%のCAGRで推移し、2030年末には55億米ドルに達すると予測されています。欧州市場は、2025年の14億米ドルから、予測期間中はCAGR 8%で推移し、2030年末には20億米ドルに達すると予測されています。

当レポートでは、世界の抗パーキンソン病薬の市場を調査し、市場概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析などをまとめています。

目次

第1章 エグゼクティブサマリー

• 市場見通し
• 調査範囲
• 市場サマリー
• 概要
• 現在の市場シナリオ
• セグメント分析
• 新興技術
• 結論

第2章 市場概要

• 概要と市場定義
• 病態生理学
• 症状
• 診断
• 治療と管理
• マクロ経済要因分析
• 人口統計学的要因
• 環境要因
• 地政学的要因
• 経済的要因
• 米国の関税が抗パーキンソン病薬市場に与える影響
• ポーターのファイブフォース分析
• サプライチェーン分析

第3章 市場力学

• 市場力学
• 市場促進要因
• パーキンソン病の有病率
• アンメットニーズの高さがイノベーションにつながる
• 業界連携による研究開発の加速
• 公的および民間投資と支援の増加
• 市場抑制要因
• 抗パーキンソン病薬に伴う副作用
• 医薬品開発の高コストと低い成功率
• 市場機会
• 新興国における意識の高まり
• 堅牢なパイプライン

第4章 規制状況

• 抗パーキンソン病薬の規制面
• 米国
• 欧州
• 日本

第5章 新興技術と開発

• 新興技術
• 薬剤と医療機器の組み合わせ
• 細胞・遺伝子治療
• ワクチン
• モノクローナル抗体
• その他の併用療法
• パイプライン分析
• 重要ポイント

第6章 市場セグメンテーション分析

• 概要
• 重要ポイント
• セグメンテーションの内訳
• 市場分析：薬剤クラス別
• ドパミン作動薬
• ドパミンアゴニスト
• カテコール-O-メチルトランスフェラーゼ阻害薬
• モノアミン酸化酵素B阻害薬
• 抗コリン薬
• その他
• 地理的内訳
• 市場分析：地域別
• 重要ポイント
• 北米
• 欧州
• アジア太平洋
• その他の地域

第7章 競合情報

• 重要ポイント
• 市場シェア分析
• 戦略的取り組み
• 協定、協力、パートナーシップ
• 買収

第8章 抗パーキンソン病薬の世界市場における持続可能性：ESGの観点

• ESG：イントロダクション
• 持続可能性の動向と取り組み
• 環境
• 社会とガバナンスの取り組み
• ESGリスク評価
• 結論

第9章 付録

• 調査手法
• 出典
• 略語
• 企業プロファイル
• ABBVIE INC.
• ACADIA PHARMACEUTICALS INC.
• AMNEAL PHARMACEUTICALS LLC.
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• F. HOFFMANN-LA ROCHE LTD.
• H. LUNDBECK A/S
• KYOWA KIRIN CO. LTD.
• MERZ THERAPEUTICS
• NEUROCRINE BIOSCIENCES INC.
• NEURODERM
• NEWRON PHARMACEUTICALS SPA
• NOVARTIS AG
• PFIZER INC.
• SUPERNUS PHARMACEUTICALS INC.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• 新興スタートアップ企業/市場ディスラプター

List of Tables

• Summary Table : Global Market for Anti-Parkinson's Drugs, by Region, Through 2030
• Table 1 : NIH Funding Estimates for Parkinson's Disease Research, 2019-2024
• Table 2 : Selected List of Anti-Parkinson's Drugs in Clinical Trials
• Table 3 : Global Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 4 : Global Market for Dopaminergic Drugs, by Region, Through 2030
• Table 5 : Classification of Dopamine Agonists
• Table 6 : Global Market for Dopamine Agonist Drugs, by Region, Through 2030
• Table 7 : Global Market for Catechol-O-Methyl Transferase (COMT) Inhibitor Drugs, by Region, Through 2030
• Table 8 : Global Market for Monoamine Oxidase B (MAO-B) Inhibitor Drugs, by Region, Through 2030
• Table 9 : Global Market for Anticholinergic Drugs, by Region, Through 2030
• Table 10 : List of Other Common Drugs
• Table 11 : Global Market for Other Anti-Parkinson's Drugs, by Region, Through 2030
• Table 12 : Global Market for Anti-Parkinson's Drugs, by Region, Through 2030
• Table 13 : North American Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 14 : North American Market for Anti-Parkinson's Drugs, by Country, Through 2030
• Table 15 : U.S. Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 16 : Canadian Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 17 : Mexican Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 18 : European Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 19 : European Market for Anti-Parkinson's Drugs, by Country, Through 2030
• Table 20 : German Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 21 : U.K Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 22 : French Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 23 : Spanish Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 24 : Italian Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 25 : Rest of Europe Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 26 : Asia-Pacific Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 27 : Asia-Pacific Market for Anti-Parkinson's Drugs, by Country, Through 2030
• Table 28 : Chinese Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 29 : Japanese Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 30 : Indian Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 31 : South Korean Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 32 : Australian Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 33 : Rest of Asia-Pacific Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 34 : RoW Market for Anti-Parkinson's Drugs, by Drug Class, Through 2030
• Table 35 : RoW Market for Anti-Parkinson's Drugs, by Country, Through 2030
• Table 36 : Agreements, Collaborations and Partnerships in the Anti-Parkinson's Drugs Market, 2021-2025
• Table 37 : Acquisitions in the Anti-Parkinson's Drugs Market, 2021-2024
• Table 38 : Environmental Initiatives by Various Anti-Parkinson's Drugs Manufacturers
• Table 39 : Key Social and Governance Issues in Anti-Parkinson's Drugs Market
• Table 40 : ESG Risk Rankings for Anti-Parkinson's Drugs Companies, 2024
• Table 41 : Information Sources in this Report
• Table 42 : Abbreviations Used in the Global Anti-Parkinson's Drugs Market
• Table 43 : AbbVie Inc.: Company Snapshot
• Table 44 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
• Table 45 : AbbVie Inc.: Product Portfolio
• Table 46 : AbbVie Inc.: News/Key Developments, 2023 and 2024
• Table 47 : Acadia Pharmaceuticals Inc.: Company Snapshot
• Table 48 : Acadia Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 49 : Acadia Pharmaceuticals Inc.: Product Portfolio
• Table 50 : Acadia Pharmaceuticals Inc.: News/Key Developments, 2022-2024
• Table 51 : Amneal Pharmaceuticals LLC.: Company Snapshot
• Table 52 : Amneal Pharmaceuticals LLC.: Financial Performance, FY 2023 and 2024
• Table 53 : Amneal Pharmaceuticals LLC.: Product Portfolio
• Table 54 : Amneal Pharmaceuticals LLC.: News/Key Developments, 2023 and 2024
• Table 55 : Boehringer Ingelheim International GmbH: Company Snapshot
• Table 56 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2023 and 2024
• Table 57 : Boehringer Ingelheim International GmbH: Product Portfolio
• Table 58 : Boehringer Ingelheim International GmbH: News/Key Developments, 2024 and 2025
• Table 59 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 60 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 61 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 62 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024
• Table 63 : H. Lundbeck A/S: Company Snapshot
• Table 64 : H. Lundbeck A/S: Financial Performance, FY 2023 and 2024
• Table 65 : H. Lundbeck A/S: Product Portfolio
• Table 66 : H. Lundbeck A/S: News/Key Developments, 2021-2024
• Table 67 : Kyowa Kirin Co. Ltd.: Company Snapshot
• Table 68 : Kyowa Kirin Co. Ltd.: Financial Performance, FY 2023 and 2024
• Table 69 : Kyowa Kirin Co. Ltd.: Product Portfolio
• Table 70 : Kyowa Kirin Co. Ltd.: News/Key Developments, 2022
• Table 71 : Merz Therapeutics: Company Snapshot
• Table 72 : Merz Therapeutics: Product Portfolio
• Table 73 : Merz Therapeutics: News/Key Developments, 2024
• Table 74 : Neurocrine Biosciences Inc.: Company Snapshot
• Table 75 : Neurocrine Biosciences Inc.: Financial Performance, FY 2023 and 2024
• Table 76 : Neurocrine Biosciences Inc.: Product Portfolio
• Table 77 : Neurocrine Biosciences Inc.: News/Key Developments, 2023
• Table 78 : NeuroDerm: Company Snapshot
• Table 79 : NeuroDerm: Product Portfolio
• Table 80 : NeuroDerm: News/Key Developments, 2024 and 2025
• Table 81 : Newron Pharmaceuticals SpA: Company Snapshot
• Table 82 : Newron Pharmaceuticals SpA: Financial Performance, FY 2023 and 2024
• Table 83 : Newron Pharmaceuticals SpA: Product Portfolio
• Table 84 : Newron Pharmaceuticals SpA: News/Key Developments, 2021
• Table 85 : Novartis AG: Company Snapshot
• Table 86 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 87 : Novartis AG: Product Portfolio
• Table 88 : Novartis AG: News/Key Developments, 2021-2024
• Table 89 : Pfizer Inc.: Company Snapshot
• Table 90 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
• Table 91 : Pfizer Inc.: Product Portfolio
• Table 92 : Supernus Pharmaceuticals Inc.: Company Snapshot
• Table 93 : Supernus Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 94 : Supernus Pharmaceuticals Inc.: Product Portfolio
• Table 95 : Supernus Pharmaceuticals Inc.: News/Key Developments, 2021-2025
• Table 96 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
• Table 97 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
• Table 98 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
• Table 99 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2021
• Table 100 : List of Few Emerging Startups in the Anti-Parkinson's Drugs Market

List of Figures

• Summary Figure : Global Market Shares of Anti-Parkinson's Drugs, by Region, 2024
• Figure 1 : Porter's Five Forces Analysis of the Anti-Parkinson's Drugs Market
• Figure 2 : Supply Chain Process of Pharmaceutical Drugs
• Figure 3 : Market Dynamics of Anti-Parkinson's Drugs
• Figure 4 : Clinical Trial Analysis, as of April 2025
• Figure 5 : Number of Active PD Drug Trials, by Phase and Categories, 2024
• Figure 6 : Global Market Shares of Anti-Parkinson's Drugs, by Drug Class, 2024
• Figure 7 : Global Market Shares of Anti-Parkinson's Drugs, by Region, 2024
• Figure 8 : North American Market Shares of Anti-Parkinson's Drugs, by Country, 2024
• Figure 9 : European Market Shares of Anti-Parkinson's Drugs, by Country, 2024
• Figure 10 : Asia-Pacific Market Shares of Anti-Parkinson's Drugs, by Country, 2024
• Figure 11 : Global Market Shares of Anti-Parkinson's Drugs, by Key Companies, 2024
• Figure 12 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 13 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 14 : Acadia Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 15 : Amneal Pharmaceuticals LLC.: Revenue Share, by Business Unit, FY 2024
• Figure 16 : Boehringer Ingelheim International GmbH: Revenue Share, by Business Unit,FY 2024
• Figure 17 : Boehringer Ingelheim International GmbH: Revenue Share, by Region/Country,FY 2024
• Figure 18 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
• Figure 19 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
• Figure 20 : H. Lundbeck A/S: Revenue Share, by Business Unit, FY 2024
• Figure 21 : H. Lundbeck A/S: Revenue Share, by Country/Region, FY 2024
• Figure 22 : Kyowa Kirin Co. Ltd.: Revenue Share by Country/Region, FY 2024
• Figure 23 : Neurocrine Biosciences Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 24 : Newron Pharmaceuticals SpA: Revenue Share, by Business Unit, FY 2024
• Figure 25 : Novartis AG: Revenue Share, by Business Unit, FY 2024
• Figure 26 : Novartis AG: Revenue Share, by Country/Region, FY 2024
• Figure 27 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 28 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 29 : Supernus Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 30 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Unit, 2024

The global market for anti-Parkinson’s drugs is projected to grow from $6.1 billion in 2025 to reach $9.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030.

The North American market for anti-Parkinson’s drugs is projected to grow from $3.5 billion in 2025 to reach $5.5 billion by the end of 2030, at a CAGR of 9.5% from 2025 to 2030.

The European market for anti-Parkinson’s drugs is projected to grow from $1.4 billion in 2025 to reach $2.0 billion by the end of 2030, at a CAGR of 8% from 2025 to 2030.

Report Scope

The report provides an overview of the global anti-Parkinson's drugs market and analyzes market trends. It includes global revenue ($ millions) for the base year data of 2024, estimated data for 2025 and forecast of compound annual growth rates (CAGRs) from 2025 to 2030. The market is segmented by drug class (based on mechanisms of action) and regions. By drug class, the market is segmented into dopaminergic, dopamine agonists, catechol-O-methyltransferase (COMT) inhibitors, monoamine oxidase-B (MAO-B) inhibitors, anticholinergic and others. The regions covered in this study are North America, Europe, Asia-Pacific, the Middle East and Africa, and South America, focusing on the major countries in these regions. The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe. Asia-Pacific includes China, Japan, India, South Korea, Australia and the Rest of Asia-Pacific. The report focuses on the driving trends and challenges affecting the market. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report also includes an analysis of the competitive landscape and company profiles that address such details as overview, key financials, product portfolio and recent developments of key market businesses.

Report Includes

• 46 data tables and 55 additional tables
• An overview of the global market for anti-Parkinson's drugs
• In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, forecasts for 2030 and projections of compound annual growth rates (CAGRs) through 2030
• Evaluation of the current market size and revenue growth prospects specific to anti-Parkinson's drugs, accompanied by a market share analysis by drug class and region
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios, and ESG trends in the market
• Insights derived from Porter's Five Forces model, global value chain and case studies
• Patent analysis and emerging trends and developments in patent activity
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Identification of companies best positioned to meet this demand due to their proprietary technologies, M&As, joint ventures and other strategic alliances
• Descriptive profiles of leading companies, including AbbVie Inc., Amneal Pharmaceuticals LLC., Acadia Pharmaceuticals Inc., Supernus Pharmaceuticals Inc., and Teva Pharmaceutical Industries Co. Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Overview
• Current Market Scenario
• Segmental Analysis
• Emerging Technologies
• Conclusion

Chapter 2 Market Overview

• Overview and Market Definition
• Pathophysiology
• Symptoms
• Diagnosis
• Treatment and Management
• Macroeconomic Factors Analysis
• Demographic Factors
• Environmental Factors
• Geopolitical Factors
• Economic Factors
• Impact of U.S. Tariffs on the Anti-Parkinson's Drugs Market
• Porter's Five Forces Analysis
• Potential for New Entrants (Low to Moderate)
• Bargaining Power of Suppliers (Moderate to High)
• Bargaining Power of Buyers (Moderate)
• Threat of Substitute Products or Services (Moderate to High)
• Industry Rivalry (High)
• Supply Chain Analysis
• Research and Development (R&D)
• Manufacturing
• Packaging
• Wholesale Distributors and Repackagers
• Pharmacies
• Dispensed to Consumers

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Prevalence of Parkinson's Disease
• High Unmet Treatment Need Leads to Innovation
• Industry Collaborations Accelerate R&D
• Increased Public and Private Investments and Support
• Market Restraints
• Adverse Effects Associated with Anti-Parkinson's Drugs
• High Cost of Drug Development and Low Success Rate
• Market Opportunities
• Increased Awareness in Emerging Countries
• Robust Pipeline

Chapter 4 Regulatory Landscape

• Regulatory Aspects of Anti-Parkinson's Drugs
• United States
• Europe
• Japan

Chapter 5 Emerging Technologies and Developments

• Emerging Technologies
• Drug-Device Combinations
• Cell and Gene Therapies
• Vaccine
• Monoclonal Antibodies
• Other Combination Therapies
• Pipeline Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Overview
• Key Takeaways
• Segmentation Breakdown
• Market Analysis by Drug Class
• Dopaminergic
• Dopamine Agonists
• Catechol-O-methyl Transferase Inhibitors
• Monoamine Oxidase B Inhibitors
• Anticholinergics
• Others
• Geographic Breakdown
• Market Analysis by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Key Takeaways
• Market Share Analysis
• Strategic Initiatives
• Agreements, Collaborations and Partnerships
• Acquisitions

Chapter 8 Sustainability in the Anti-Parkinson's Drugs Global Market: An ESG Perspective

• Introduction to ESG
• Sustainability Trends and Initiatives
• Environmental
• Social and Governance Initiatives
• ESG Risk Ratings
• Concluding Remarks

Chapter 9 Appendix

• Research Methodology
• Sources
• Abbreviations
• Company Profiles
• ABBVIE INC.
• ACADIA PHARMACEUTICALS INC.
• AMNEAL PHARMACEUTICALS LLC.
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• F. HOFFMANN-LA ROCHE LTD.
• H. LUNDBECK A/S
• KYOWA KIRIN CO. LTD.
• MERZ THERAPEUTICS
• NEUROCRINE BIOSCIENCES INC.
• NEURODERM
• NEWRON PHARMACEUTICALS SPA
• NOVARTIS AG
• PFIZER INC.
• SUPERNUS PHARMACEUTICALS INC.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• Emerging Start-ups/Market Disruptors